Celcuity (NASDAQ:CELC) Posts Earnings Results, Beats Expectations By $0.02 EPS

Celcuity (NASDAQ:CELC) posted its quarterly earnings data on Thursday. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02, Fidelity Earnings reports.

Shares of NASDAQ CELC traded up $0.26 during mid-day trading on Friday, reaching $14.30. 4,400 shares of the company were exchanged, compared to its average volume of 7,599. Celcuity has a 52 week low of $13.49 and a 52 week high of $29.96. The company has a quick ratio of 25.26, a current ratio of 25.25 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average price is $16.28 and its 200 day moving average price is $19.76. The stock has a market capitalization of $157.07 million, a PE ratio of -19.32 and a beta of 0.65.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

CELC has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of Celcuity from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a report on Friday, October 11th. ValuEngine raised shares of Celcuity from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd.

Celcuity Company Profile

Celcuity Inc, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United States. The company's CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it.

Further Reading: Mutual Funds

Earnings History for Celcuity (NASDAQ:CELC)

Leave a Reply

Your email address will not be published. Required fields are marked *

*